Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Evogene ( (EVGN) ) is now available.
On February 10, 2026, Evogene entered into a warrant inducement agreement with an existing institutional investor, leading to the immediate cash exercise of August 2024 Series A and Series B warrants for 3,384,616 ordinary shares at a reduced price of $1.00 per share. The transaction is expected to provide approximately $3.4 million in gross proceeds, earmarked for working capital and general corporate purposes, and is slated to close around February 11, 2026, subject to customary conditions.
In return for the early exercise, Evogene will issue 5,076,924 new unregistered Series A-1 and Series B-1 warrants, split evenly, with an exercise price of $1.25 per share and terms of five years and 18 months, respectively. The company has engaged A.G.P./Alliance Global Partners as sole financial advisor, committed to register the resale of shares underlying the new warrants, and agreed to short-term restrictions on issuing additional equity or variable-rate financings, a structure that boosts near-term liquidity while adding potential future dilution for shareholders.
The most recent analyst rating on (EVGN) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene’s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While the earnings call provided some positive insights into cost management and strategic initiatives, the company’s financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd., dual-listed on Nasdaq and TASE under the ticker EVGN, is a computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries. Its core ChemPass AI platform uses generative AI to create novel, potent molecules optimized across multiple parameters, supporting both internal product development and strategic partnerships in these end markets.
Average Trading Volume: 269,701
Technical Sentiment Signal: Sell
Current Market Cap: $9.5M
For detailed information about EVGN stock, go to TipRanks’ Stock Analysis page.